A few years later, given the evidence of HPV-mediated tumor angiogenesis, through the increasing levels of HIF-1α protein, and the upregulation of vascular endothelial growth factor (VEGF) [12], the anti-VEGF monoclonal antibody, bevacizumab, was tested in combination with platinum-based chemotherapy [13], demonstrating increased overall survival (OS: 17.0 months vs. 13.3 months; hazard ratio [HR] 0.71; 98% CI: 0.54–0.95; p = 0.004) and higher RR (48% vs. 36%, P = 0.008). The gene discussed is VEGFA; the disease is neoplasm.